bbT369
CRC-403
Phase 1 mab terminated
Quick answer
bbT369 for Diffuse Large B Cell Lymphoma (DLBCL) is a Phase 1 program (mab) at REGENERON PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- REGENERON PHARMACEUTICALS, INC.
- Indication
- Diffuse Large B Cell Lymphoma (DLBCL)
- Phase
- Phase 1
- Modality
- mab
- Status
- terminated